David Bhatt

David Bhatt has investigated mechanisms underlying CDK4/6 inhibitor efficacy and resistance in hormone receptor-positive breast cancer, focusing on the retinoblastoma (Rb) pathway and downstream cell cycle regulators. His research characterized how CDK4/6 inhibitor combinations with endocrine therapy achieve superior progression-free survival through G1 arrest and senescence induction in luminal breast cancer cells. He has studied acquired resistance mechanisms including Rb loss, CDK2 amplification, and alternative cyclin upregulation that bypass CDK4/6 inhibition, identifying potential therapeutic targets for overcoming resistance. His translational work integrates cell cycle biology with clinical outcomes data from CDK4/6 inhibitor trials in metastatic and early-stage breast cancer.